Molecular epidemiology and antimicrobials resistance mechanism of Mycoplasma genitlaium

Cover Page

Cite item

Full Text

Abstract

Currently, infections caused by Mycoplasma genitalium are ones the most common sexually transmitted infections. Their prevalence is varied from 1.3% to 15.9%. Infections caused by M. genitalium may lead to urethritis in men and a wide spectrum of diseases in women. Antibiotic resistance now is one of the most emerging problems both in the scientific and in the healthcare fields. The usage of antimicrobials inhibiting cell wall synthesis for the treatment of M. genitalium is ineffective, and resistance to macrolides and fluoroquinolones is increasing rapidly. M. genitalium infections diagnostics is complicated due to specific conditions and duration of culture methods. The usage of nucleic acid amplification techniques is the most relevant for laboratory diagnostics, and is used in existing assays. This review compiles current data on the prevalence, molecular mechanisms of pathogenesis and antibiotic resistance, as well as diagnostics methods of M. genitalium.

About the authors

Elizaveta Dmitrievna Shedko

Central Research Institute of Epidemiology

Author for correspondence.
Email: shedko@cmd.su
ORCID iD: 0000-0003-4556-7513
SPIN-code: 5438-5347
Russian Federation, Moscow

Elena Nokolaevna Goloveshkina

Central Research Institute of Epidemiology

Email: goloveshkina@cmd.su
ORCID iD: 0000-0002-0536-2874
SPIN-code: 6682-4673

PhD

Russian Federation, Moscow

Vasiliy Gennadievich Akimkin

Central Research Institute of Epidemiology

Email: akimkin@pcr.ms
ORCID iD: 0000-0003-4228-9044
SPIN-code: 4038-7455

MD

Russian Federation, Moscow

References

  1. Taylor-Robinson D., Jensen J.S. Mycoplasma genitalium: from Chrysalis to Multicolored Butterfly. Clin Microbiol Rev. 2011 Jul 1;24(3):498–514. doi: 10.1128/CMR.00006-11.
  2. Baumann L., Cina M., Egli-Gany D., Goutaki M., Halbeisen F.S., Lohrer G.-R., et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis. Sex Transm Infect. 2018 Jun;94(4):255–62. doi: 10.1136/sextrans-2017-053384.
  3. Lis R., Rowhani-Rahbar A., Manhart L.E. Mycoplasma genitalium Infection and Female Reproductive Tract Disease: A Meta-analysis. Clin Infect Dis. 2015 Aug 1;61(3):418–26. doi: 10.1093/cid/civ312.
  4. Napierala Mavedzenge S., Weiss H.A. Association of Mycoplasma genitalium and HIV infection: a systematic review and meta-analysis. AIDS. 2009 Mar;23(5):611–20. doi: 10.1097/QAD.0b013e328323da3e.
  5. Doyle M., Vodstrcil L.A., Plummer E.L., Aguirre I., Fairley C.K., Bradshaw C.S. Nonquinolone Options for the Treatment of Mycoplasma genitalium in the Era of Increased Resistance. Open Forum Infect Dis. 2020 Aug 1;7(8). doi: 10.1093/ofid/ofaa291.
  6. Munoz J.L., Goje O.J. Mycoplasma genitalium : An Emerging Sexually Transmitted Infection. Scientifica (Cairo). 2016;2016:1–5. doi: 10.1155/2016/7537318.
  7. Gnanadurai R., Fifer H. Mycoplasma genitalium: A Review. Microbiology. 2020 Jan 1;166(1):21–9. doi: 10.1099/mic.0.000830.
  8. Machalek D.A., Tao Y., Shilling H., Jensen J.S., Unemo M., Murray G., et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis. 2020 Jul; doi: 10.1016/S1473-3099(20)30154-7.
  9. De Baetselier I., Kenyon C., Vanden Berghe W., Smet H., Wouters K., Van den Bossche D., et al. An alarming high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium in Belgium: results from samples collected between 2015 and 2018. Sex Transm Infect. 2020 Aug 7;sextrans-2020-054511. doi: 10.1136/sextrans-2020-054511.
  10. Hokynar K., Hiltunen-Back E., Mannonen L., Puolakkainen M. Prevalence of Mycoplasma genitalium and mutations associated with macrolide and fluoroquinolone resistance in Finland. Int J STD AIDS. 2018 Aug 9;29(9):904–7. doi: 10.1177/0956462418764482.
  11. Jensen J.S., Cusini M., Gomberg M., Moi H. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatology Venereol. 2016 Oct;30(10):1650–6. doi: 10.1111/jdv.13849.
  12. Tagg K.A., Jeoffreys N.J., Couldwell D.L., Donald J.A., Gilbert G.L. Fluoroquinolone and Macrolide Resistance-Associated Mutations in Mycoplasma genitalium. J Clin Microbiol. 2013 Jul 1;51(7):2245–9. doi: 10.1128/JCM.00495-13.
  13. Ross J.D.C. Mycoplasma genitalium as a sexually transmitted infection: implications for screening, testing, and treatment. Sex Transm Infect. 2006 Aug 1;82(4):269–71. doi: 10.1136/sti.2005.017368.
  14. Soni S., Horner P.J. Launch of the BASHH guideline for the management of M. genitalium in adults. Sex Transm Infect. 2019 Jun 16;95(4):237–237. doi: 10.1136/sextrans-2018-053831.
  15. Потекаев Н.Н., Кисина В.И., Гущин А.Е., Гомберг М.А., Фриго Н.В., Жукова О.В., et al. Правительство москвы департамент здравоохранения города москвы инфекция , вызванная. Москва: ПРАВИТЕЛЬСТВО МОСКВЫ ДЕПАРТАМЕНТ ЗДРАВООХРАНЕНИЯ ГОРОДА МОСКВЫ; 2018. p. 28.
  16. Tully J., Cole R., Taylor-Robinson D., Rose D. A NEWLY DISCOVERED MYCOPLASMA IN THE HUMAN UROGENITAL TRACT. Lancet. 1981 Jun;317(8233):1288–91. doi: 10.1016/S0140-6736(81)92461-2.
  17. Thompson C.C., Vieira N.M., Vicente A.C.P., Thompson F.L. Towards a genome based taxonomy of Mycoplasmas. Infect Genet Evol. 2011 Oct;11(7):1798–804. doi: 10.1016/j.meegid.2011.07.020.
  18. Fookes M.C., Hadfield J., Harris S., Parmar S., Unemo M., Jensen J.S., et al. Mycoplasma genitalium: whole genome sequence analysis, recombination and population structure. BMC Genomics. 2017 Dec 28;18(1):993. doi: 10.1186/s12864-017-4399-6.
  19. Fraser C.M., Gocayne J.D., White O., Adams M.D., Clayton R.A., Fleischmann R.D., et al. The Minimal Gene Complement of Mycoplasma genitalium. Science (80- ). 1995 Oct 20;270(5235):397–404. doi: 10.1126/science.270.5235.397.
  20. CORDOVA C.M.M., HOELTGEBAUM D.L., MACHADO L.D.P.N., SANTOS L. DOS. Molecular biology of mycoplasmas: from the minimum cell concept to the artificial cell. An Acad Bras Cienc. 2016 Apr 29;88(suppl 1):599–607. doi: 10.1590/0001-3765201620150164.
  21. Razin S. The minimal cellular genome of mycoplasma. Indian J Biochem Biophys. 34(1–2):124–30.
  22. McGowin C.L., Totten P.A. The Unique Microbiology and Molecular Pathogenesis of Mycoplasma genitalium. J Infect Dis. 2017 Jul 15;216(suppl_2):S382–8. doi: 10.1093/infdis/jix172.
  23. Ma L., Jensen J.S., Mancuso M., Hamasuna R., Jia Q., McGowin C.L., et al. Genetic Variation in the Complete MgPa Operon and Its Repetitive Chromosomal Elements in Clinical Strains of Mycoplasma genitalium. Hartskeerl RA, editor. PLoS One. 2010 Dec 20;5(12):e15660. doi: 10.1371/journal.pone.0015660.
  24. Iverson-Cabral S.L., Manhart L.E., Totten P.A. Detection of Mycoplasma genitalium-Reactive Cervicovaginal Antibodies among Infected Women. Clin Vaccine Immunol. 2011 Oct;18(10):1783–6. doi: 10.1128/CVI.05174-11.
  25. Wood G.E., Iverson-Cabral S.L., Gillespie C.W., Lowens M.S., Manhart L.E., Totten P.A. Sequence variation and immunogenicity of the Mycoplasma genitalium MgpB and MgpC adherence proteins during persistent infection of men with non-gonococcal urethritis. Brissette CA, editor. PLoS One. 2020 Oct 12;15(10):e0240626. doi: 10.1371/journal.pone.0240626.
  26. Iverson-Cabral S.L., Astete S.G., Cohen C.R., Rocha E.P.C., Totten P.A. Intrastrain Heterogeneity of the mgpB Gene in Mycoplasma genitalium Is Extensive In Vitro and In Vivo and Suggests that Variation Is Generated via Recombination with Repetitive Chromosomal Sequences. Infect Immun. 2006 Jul;74(7):3715–26. doi: 10.1128/IAI.00239-06.
  27. Peterson S.N., Bailey C.C., Jensen J.S., Borre M.B., King E.S., Bott K.F., et al. Characterization of repetitive DNA in the Mycoplasma genitalium genome: possible role in the generation of antigenic variation. Proc Natl Acad Sci. 1995 Dec 5;92(25):11829–33. doi: 10.1073/pnas.92.25.11829.
  28. Iverson-Cabral S.L., Astete S.G., Cohen C.R., Totten P.A. mgpB and mgpC sequence diversity in Mycoplasma genitalium is generated by segmental reciprocal recombination with repetitive chromosomal sequences. Mol Microbiol. 2007 Oct;66(1):55–73. doi: 10.1111/j.1365-2958.2007.05898.x.
  29. Burgos R., Totten P.A. Characterization of the Operon Encoding the Holliday Junction Helicase RuvAB from Mycoplasma genitalium and Its Role in mgpB and mgpC Gene Variation. J Bacteriol. 2014 Apr 15;196(8):1608–18. doi: 10.1128/JB.01385-13.
  30. Burgos R., Totten P.A. MG428 is a novel positive regulator of recombination that triggers mgpB and mgpC gene variation in M ycoplasma genitalium. Mol Microbiol. 2014 Oct;94(2):290–306. doi: 10.1111/mmi.12760.
  31. Torres-Puig S., Broto A., Querol E., Piñol J., Pich O.Q. A novel sigma factor reveals a unique regulon controlling cell-specific recombination in Mycoplasma genitalium. Nucleic Acids Res. 2015 May 26;43(10):4923–36. doi: 10.1093/nar/gkv422.
  32. Torres-Puig S., Martínez-Torró C., Granero-Moya I., Querol E., Piñol J., Pich O.Q. Activation of σ20-dependent recombination and horizontal gene transfer in Mycoplasma genitalium. DNA Res. 2018 Aug 1;25(4):383–93. doi: 10.1093/dnares/dsy011.
  33. Christodoulides A., Gupta N., Yacoubian V., Maithel N., Parker J., Kelesidis T. The Role of Lipoproteins in Mycoplasma-Mediated Immunomodulation. Front Microbiol. 2018 Jul 31;9. doi: 10.3389/fmicb.2018.01682.
  34. Agarwal A., Rana M., Qiu E., AlBunni H., Bui A.D., Henkel R. Role of oxidative stress, infection and inflammation in male infertility. Andrologia. 2018 Dec;50(11):e13126. doi: 10.1111/and.13126.
  35. McGowin C.L., Ma L., Martin D.H., Pyles R.B. Mycoplasma genitalium-Encoded MG309 Activates NF-κB via Toll-Like Receptors 2 and 6 To Elicit Proinflammatory Cytokine Secretion from Human Genital Epithelial Cells. Infect Immun. 2009 Mar;77(3):1175–81. doi: 10.1128/IAI.00845-08.
  36. Dehon P.M., McGowin C.L. The Immunopathogenesis of Mycoplasma genitalium Infections in Women. Sex Transm Dis. 2017 Jul;44(7):428–32. doi: 10.1097/OLQ.0000000000000621.
  37. Ito S., Mizutani K., Seike K., Sugawara T., Tsuchiya T., Yasuda M., et al. Prediction of the persistence of Mycoplasma genitalium after antimicrobial chemotherapy by quantification of leukocytes in first-void urine from patients with non-gonococcal urethritis. J Infect Chemother. 2014 May;20(5):298–302. doi: 10.1016/j.jiac.2014.01.002.
  38. Aparicio D., Torres-Puig S., Ratera M., Querol E., Piñol J., Pich O.Q., et al. Mycoplasma genitalium adhesin P110 binds sialic-acid human receptors. Nat Commun. 2018 Dec 26;9(1):4471. doi: 10.1038/s41467-018-06963-y.
  39. Scheffer M.P., Gonzalez-Gonzalez L., Seybert A., Ratera M., Kunz M., Valpuesta J.M., et al. Structural characterization of the NAP; the major adhesion complex of the human pathogen Mycoplasma genitalium. Mol Microbiol. 2017 Sep;105(6):869–79. doi: 10.1111/mmi.13743.
  40. Aparicio D., Scheffer M.P., Marcos-Silva M., Vizarraga D., Sprankel L., Ratera M., et al. Structure and mechanism of the Nap adhesion complex from the human pathogen Mycoplasma genitalium. Nat Commun. 2020 Dec 8;11(1):2877. doi: 10.1038/s41467-020-16511-2.
  41. Deng X., Dai P., Yu M., Chen L., Zhu C., You X., et al. Cyclophilin A is the potential receptor of the Mycoplasma genitalium adhesion protein. Int J Med Microbiol. 2018 Apr;308(3):405–12. doi: 10.1016/j.ijmm.2018.03.001.
  42. Hilmarsdóttir I., Arnardóttir E.M., Jóhannesdóttir E.R., Valsdóttir F., Golparian D., Hadad R., et al. Prevalence of Mycoplasma genitalium and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima Mycoplasma genitalium Assays for Diagnosis. Munson E, editor. J Clin Microbiol. 2020 Jul 1;58(9). doi: 10.1128/JCM.01084-20.
  43. Bachmann L.H., Kirkcaldy R.D., Geisler W.M., Wiesenfeld H.C., Manhart L.E., Taylor S.N., et al. Prevalence of Mycoplasma genitalium Infection, Antimicrobial Resistance Mutations, and Symptom Resolution Following Treatment of Urethritis. Clin Infect Dis. 2020 Mar 18; doi: 10.1093/cid/ciaa293.
  44. Fernández-Huerta M., Barberá M.-J., Esperalba J., Fernandez-Naval C., Vall-Mayans M., Arando M., et al. Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study. Sex Transm Infect. 2019 Aug 26;sextrans-2019-054124. doi: 10.1136/sextrans-2019-054124.
  45. Broad C.E., Furegato M., Harrison M.A., Pond M.J., Tan N., Okala S., et al. High prevalence of coinfection of azithromycin-resistant Mycoplasma genitalium with other STIs: a prospective observational study of London-based symptomatic and STI-contact clinic attendees. Sex Transm Infect. 2020 May 11;sextrans-2019-054356. doi: 10.1136/sextrans-2019-054356.
  46. Güralp O., Bostancı A., Özerkman Başaran E., Schild-Suhren M., Kaya B. Evaluation of the prevalence of sexually transmitted bacterial pathogens in Northern Cyprus by nucleic acid amplification tests, and investigation of the relationship between these pathogens and cervicitis. J Turkish Soc Obstet Gynecol. 2020 Dec 28;16(4):242–8. doi: 10.4274/tjod.galenos.2019.80269.
  47. Bernier A., Rumyantseva T., Reques L., Volkova N., Kyburz Y., Maximov O., et al. HIV and other sexually transmitted infections among female sex workers in Moscow (Russia): prevalence and associated risk factors. Sex Transm Infect. 2020 Mar 18; doi: 10.1136/sextrans-2019-054299.
  48. Leli C., Mencacci A., Latino M.A., Clerici P., Rassu M., Perito S., et al. Prevalence of cervical colonization by Ureaplasma parvum, Ureaplasma urealyticum , Mycoplasma hominis and Mycoplasma genitalium in childbearing age women by a commercially available multiplex real-time PCR: An Italian observational multicentre study. J Microbiol Immunol Infect. 2018 Apr;51(2):220–5. doi: 10.1016/j.jmii.2017.05.004.
  49. Nye M.B., Harris A.B., Pherson A.J., Cartwright C.P. Prevalence of Mycoplasma genitalium infection in women with bacterial vaginosis. BMC Womens Health. 2020 Dec 26;20(1):62. doi: 10.1186/s12905-020-00926-6.
  50. Rahimkhani M., Mordadi A., Gilanpour M. Detection of urinary Chlamydia trachomatis, Mycoplasma genitalium and human papilloma virus in the first trimester of pregnancy by PCR method. Ann Clin Microbiol Antimicrob. 2018 Dec 4;17(1):25. doi: 10.1186/s12941-018-0276-7.
  51. Latimer R.L., Shilling H.S., Vodstrcil L.A., Machalek D.A., Fairley C.K., Chow E.P.F., et al. Prevalence of Mycoplasma genitalium by anatomical site in men who have sex with men: a systematic review and meta-analysis. Sex Transm Infect. 2020 Apr 27;sextrans-2019-054310. doi: 10.1136/sextrans-2019-054310.
  52. Chopra I., Roberts M. Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. Microbiol Mol Biol Rev. 2001 Jun 1;65(2):232–60. doi: 10.1128/MMBR.65.2.232-260.2001.
  53. van der Schalk T.E., Braam J.F., Kusters J.G. Molecular basis of antimicrobial resistance in Mycoplasma genitalium. Int J Antimicrob Agents. 2020 Apr;55(4):105911. doi: 10.1016/j.ijantimicag.2020.105911.
  54. Manhart L.E., Jensen J.S., Bradshaw C.S., Golden M.R., Martin D.H. Efficacy of Antimicrobial Therapy for Mycoplasma genitalium Infections. Clin Infect Dis. 2015 Dec 15;61(suppl 8):S802–17. doi: 10.1093/cid/civ785.
  55. Deguchi T., Ito S., Hagiwara N., Yasuda M., Maeda S. Antimicrobial chemotherapy of Mycoplasma genitalium -positive non-gonococcal urethritis. Expert Rev Anti Infect Ther. 2012 Jul 10;10(7):791–803. doi: 10.1586/eri.12.38.
  56. Unemo M., Jensen J.S. Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nat Rev Urol. 2017 Mar 10;14(3):139–52. doi: 10.1038/nrurol.2016.268.
  57. Dinos G.P. The macrolide antibiotic renaissance. Br J Pharmacol. 2017 Sep;174(18):2967–83. doi: 10.1111/bph.13936.
  58. Bulkley D., Innis C.A., Blaha G., Steitz T.A. Revisiting the structures of several antibiotics bound to the bacterial ribosome. Proc Natl Acad Sci. 2010 Oct 5;107(40):17158–63. doi: 10.1073/pnas.1008685107.
  59. Tenson T., Lovmar M., Ehrenberg M. The Mechanism of Action of Macrolides, Lincosamides and Streptogramin B Reveals the Nascent Peptide Exit Path in the Ribosome. J Mol Biol. 2003 Jul;330(5):1005–14. doi: 10.1016/S0022-2836(03)00662-4.
  60. Ramu H., Vázquez-Laslop N., Klepacki D., Dai Q., Piccirilli J., Micura R., et al. Nascent Peptide in the Ribosome Exit Tunnel Affects Functional Properties of the A-Site of the Peptidyl Transferase Center. Mol Cell. 2011 Feb;41(3):321–30. doi: 10.1016/j.molcel.2010.12.031.
  61. Braam J.F., van Marm S., Severs T.T., Belousov Y., Mahoney W., Kusters J.G. Sensitive and specific assay for the simultaneous detection of Mycoplasma genitalium and macrolide resistance-associated mutations. Eur J Clin Microbiol Infect Dis. 2018 Nov 1;37(11):2137–44. doi: 10.1007/s10096-018-3350-3.
  62. Berisio R., Corti N., Pfister P., Yonath A., Böttger E.C. 23S rRNA 2058A→G Alteration Mediates Ketolide Resistance in Combination with Deletion in L22. Antimicrob Agents Chemother. 2006 Nov;50(11):3816–23. doi: 10.1128/AAC.00767-06.
  63. Vester B., Douthwaite S. Macrolide Resistance Conferred by Base Substitutions in 23S rRNA. Antimicrob Agents Chemother. 2001 Jan 1;45(1):1–12. doi: 10.1128/AAC.45.1.1-12.2001.
  64. Fyfe C., Grossman T.H., Kerstein K., Sutcliffe J. Resistance to Macrolide Antibiotics in Public Health Pathogens. Cold Spring Harb Perspect Med. 2016 Oct;6(10):a025395. doi: 10.1101/cshperspect.a025395.
  65. Smith A., Pennefather P.M., Kaye S.B., Hart C.A. Fluoroquinolones. Drugs. 2001;61(6):747–61. doi: 10.2165/00003495-200161060-00004.
  66. Ball P., Fernald A., Tillotson G. Therapeutic advances of new fluoroquinolones. Expert Opin Investig Drugs. 1998 May 23;7(5):761–83. doi: 10.1517/13543784.7.5.761.
  67. Blondeau J.M. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004 Mar;49(2):S73–8. doi: 10.1016/j.survophthal.2004.01.005.
  68. Maruri F., Sterling T.R., Kaiga A.W., Blackman A., van der Heijden Y.F., Mayer C., et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012 Apr;67(4):819–31. doi: 10.1093/jac/dkr566.
  69. Sanfilippo C.M., Hesje C.K., Haas W., Morris T.W. Topoisomerase Mutations That Are Associated with High-Level Resistance to Earlier Fluoroquinolones in Staphylococcus aureus Have Less Effect on the Antibacterial Activity of Besifloxacin. Chemotherapy. 2011;57(5):363–71. doi: 10.1159/000330858.
  70. Aldred K.J., Kerns R.J., Osheroff N. Mechanism of Quinolone Action and Resistance. Biochemistry. 2014 Mar 18;53(10):1565–74. doi: 10.1021/bi5000564.
  71. Shipitsyna E., Rumyantseva T., Golparian D., Khayrullina G., Lagos A.C., Edelstein I., et al. Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia. Browning GF, editor. PLoS One. 2017 Apr 13;12(4):e0175763. doi: 10.1371/journal.pone.0175763.
  72. Murray G.L., Bradshaw C.S., Bissessor M., Danielewski J., Garland S.M., Jensen J.S., et al. Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium. Emerg Infect Dis. 2017 May;23(5):809–12. doi: 10.3201/eid2305.161745.
  73. Shimada Y., Deguchi T., Nakane K., Masue T., Yasuda M., Yokoi S., et al. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance. Int J Antimicrob Agents. 2010 Sep;36(3):255–8. doi: 10.1016/j.ijantimicag.2010.05.011.
  74. Workowski K.A., Bolan G.A., Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm reports Morb Mortal Wkly report Recomm reports. 2015 Jun 5;64(RR-03):1–137.
  75. (Ginebra O.M. de la S., Suiza), Staff W.H.O., Zdrowia Ś.O., Organization W.H., UNAIDS. Guidelines for the management of sexually transmitted infections. World Health Organization; 2003.
  76. Totten P.A., Jensen N.L., Khosropour C.M. Azithromycin and doxycycline resistance profiles of recent clinical isolates of Mycoplasma genitalium. In: STI & AIDS World Congress Joint Meeting of the 20th International Society of Sexually Transmitted Disease Research. 2013.
  77. Fernández-Huerta M., Vall M., Fernández-Naval C., Barberá M.-J., Arando M., López L., et al. Mycoplasma genitalium macrolide resistance update: Rate among a 2016–2017 cohort of patients in Barcelona, Spain. Enferm Infecc Microbiol Clin. 2020 Mar;38(3):99–104. doi: 10.1016/j.eimc.2019.06.008.
  78. Lau A., Bradshaw C.S., Lewis D., Fairley C.K., Chen M.Y., Kong F.Y.S., et al. The Efficacy of Azithromycin for the Treatment of Genital Mycoplasma genitalium : A Systematic Review and Meta-analysis. Clin Infect Dis. 2015 Nov 1;61(9):1389–99. doi: 10.1093/cid/civ644.
  79. Bradley I., Varma R., Knight V., Iliakis D., McNally L., Jalocon D., et al. Prevalence of rectal Mycoplasma genitalium and macrolide resistance in men who have sex with men attending Sydney Sexual Health Centre. Sex Health. 2020;17(2):114. doi: 10.1071/SH18221.
  80. Van Praet J.T., Steyaert S., Vandecasteele S., Van Den Bergh B., Mahieu H., De Buyser S., et al. Mycoplasma genitalium acquisition and macrolide resistance after initiation of HIV pre-exposure prophylaxis in men who have sex with men. Sex Transm Infect. 2020 Sep;96(6):396–8. doi: 10.1136/sextrans-2019-054335.
  81. Mulligan V., Lynagh Y., Clarke S., Unemo M., Crowley B. Prevalence, Macrolide Resistance, and Fluoroquinolone Resistance in Mycoplasma genitalium in Men Who Have Sex With Men Attending an Sexually Transmitted Disease Clinic in Dublin, Ireland in 2017–2018. Sex Transm Dis. 2019 Apr;46(4):e35–7. doi: 10.1097/OLQ.0000000000000940.
  82. Couldwell D.L., Jalocon D., Power M., Jeoffreys N.J., Chen S.C.-A., Lewis D.A. Mycoplasma genitalium : high prevalence of resistance to macrolides and frequent anorectal infection in men who have sex with men in western Sydney. Sex Transm Infect. 2018 Sep;94(6):406–10. doi: 10.1136/sextrans-2017-053480.
  83. Fernández-Huerta M., Barberá M.J., Serra-Pladevall J., Esperalba J., Martínez-Gómez X., Centeno C., et al. Mycoplasma genitalium and antimicrobial resistance in Europe: a comprehensive review. Int J STD AIDS. 2020 Mar 30;31(3):190–7. doi: 10.1177/0956462419890737.
  84. Dumke R., Ziegler T., Abbasi-Boroudjeni N., Rust M., Glaunsinger T. Prevalence of macrolide- and fluoroquinolone-resistant Mycoplasma genitalium strains in clinical specimens from men who have sex with men of two sexually transmitted infection practices in Berlin, Germany. J Glob Antimicrob Resist. 2019 Sep;18:118–21. doi: 10.1016/j.jgar.2019.06.015.
  85. Read T.R.H., Fairley C.K., Murray G.L., Jensen J.S., Danielewski J., Worthington K., et al. Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation. Clin Infect Dis. 2019 Feb 1;68(4):554–60. doi: 10.1093/cid/ciy477.
  86. Sweeney E.L., Trembizki E., Bletchly C., Bradshaw C.S., Menon A., Francis F., et al. Levels of Mycoplasma genitalium Antimicrobial Resistance Differ by Both Region and Gender in the State of Queensland, Australia: Implications for Treatment Guidelines. Munson E, editor. J Clin Microbiol. 2019 Jan 2;57(3). doi: 10.1128/JCM.01555-18.
  87. Pitt R., Unemo M., Sonnenberg P., Alexander S., Beddows S., Cole M.J., et al. Antimicrobial resistance in Mycoplasma genitalium sampled from the British general population. Sex Transm Infect. 2020 Sep;96(6):464–8. doi: 10.1136/sextrans-2019-054129.
  88. Spiller O.B., Rees C.L., Morris D.J., Davies R.L., Jones L.C. Mycoplasma genitalium prevalence in Welsh sexual health patients: Low antimicrobial resistance markers and no association of symptoms to bacterial load. Microb Pathog. 2020 Feb;139:103872. doi: 10.1016/j.micpath.2019.103872.
  89. Deguchi T., Ito S., Yasuda M., Sato Y., Uchida C., Sawamura M., et al. Surveillance of the prevalence of macrolide and/or fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Japan. J Infect Chemother. 2018 Nov;24(11):861–7. doi: 10.1016/j.jiac.2018.08.009.
  90. Li W.N., Shi L., Long X.Y., Li Y., Zhu W.B., Liu G. Mycoplasma genitalium incidence, treatment failure, and resistance: a retrospective survey of men of infertile couples from a hospital in China. Andrology. 2020 Jan 12;8(1):91–100. doi: 10.1111/andr.12646.
  91. Romanova I. V., Kisina V.I., Khayrullina G.A., Frigo N. V., Zhukova O. V., Gushchin A.E. The prevalence and type of mutations of in dermatovenereological patients from the Moscow region for 2014‒2018. Klin dermatologiya i Venerol. 2020;19(1):7. doi: 10.17116/klinderma2020190117.
  92. Hamasuna R., Osada Y., Jensen J.S. Isolation of Mycoplasma genitalium from First-Void Urine Specimens by Coculture with Vero Cells. J Clin Microbiol. 2007 Mar 1;45(3):847–50. doi: 10.1128/JCM.02056-06.
  93. Baseman J.B., Cagle M., Korte J.E., Herrera C., Rasmussen W.G., Baseman J.G., et al. Diagnostic Assessment of Mycoplasma genitalium in Culture-Positive Women. J Clin Microbiol. 2004 Jan 1;42(1):203–11. doi: 10.1128/JCM.42.1.203-211.2004.
  94. Conway R., Cook S., Suneeta S. Antibiotic treatment of Mycoplasma genitalium infection. Pharm J. 2019; doi: 10.1211/PJ.2019.20206592.
  95. Lind K., Lindhardt B.O., Schütten H.J., Blom J., Christiansen C. Serological cross-reactions between Mycoplasma genitalium and Mycoplasma pneumoniae. J Clin Microbiol. 1984 Dec;20(6):1036–43. doi: 10.1128/JCM.20.6.1036-1043.1984.
  96. Waites K.B., Xiao L., Paralanov V., Viscardi R.M., Glass J.I. Molecular Methods for the Detection of Mycoplasma and Ureaplasma Infections in Humans. J Mol Diagnostics. 2012 Sep;14(5):437–50. doi: 10.1016/j.jmoldx.2012.06.001.
  97. Su J.P., Tan L.Y., Garland S.M., Tabrizi S.N., Mokany E., Walker S., et al. Evaluation of the SpeeDx ResistancePlus MG Diagnostic Test for Mycoplasma genitalium on the Applied Biosystems 7500 Fast Quantitative PCR Platform. Onderdonk AB, editor. J Clin Microbiol. 2017 Nov 1;56(1). doi: 10.1128/JCM.01245-17.
  98. Le Roy C., Bébéar C., Pereyre S. Clinical Evaluation of Three Commercial PCR Assays for the Detection of Macrolide Resistance in Mycoplasma genitalium. Munson E, editor. J Clin Microbiol. 2019 Dec 4;58(2). doi: 10.1128/JCM.01478-19.
  99. Shipitsyna E., Unemo M. A profile of the FDA-approved and CE/IVD-marked Aptima Mycoplasma genitalium assay (Hologic) and key priorities in the management of M. genitalium infections. Expert Rev Mol Diagn. 2020 Oct 23;14737159.2020.1842198. doi: 10.1080/14737159.2020.1842198.
  100. de Salazar A., Espadafor B., Fuentes-López A., Barrientos-Durán A., Salvador L., Álvarez M., et al. Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections. Bruisten SM, editor. PLoS One. 2019 Sep 12;14(9):e0222439. doi: 10.1371/journal.pone.0222439.
  101. Le Roy C., Le Hen I., Clerc M., Arfel V., Normandin F., Bébéar C., et al. The first performance report for the Bio-Rad Dx CT/NG/MG assay for simultaneous detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in urogenital samples. J Microbiol Methods. 2012 Jun;89(3):193–7. doi: 10.1016/j.mimet.2012.03.009.
  102. Rumyantseva T., Golparian D., Nilsson C.S., Johansson E., Falk M., Fredlund H., et al. Evaluation of the new AmpliSens multiplex real-time PCR assay for simultaneous detection of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium , and Trichomonas vaginalis. APMIS. 2015 Oct;123(10):879–86. doi: 10.1111/apm.12430.
  103. Van Der Pol B., Waites K.B., Xiao L., Taylor S.N., Rao A., Nye M., et al. Mycoplasma genitalium Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test. Munson E, editor. J Clin Microbiol. 2020 Mar 25;58(6). doi: 10.1128/JCM.02124-19.
  104. Shen C.-H. Amplification of Nucleic Acids. In: Diagnostic Molecular Biology. Elsevier; 2019. p. 215–47. doi: 10.1016/B978-0-12-802823-0.00009-2.
  105. Sooknanan R., Malek L.T. NASBA. Nat Biotechnol. 1995 Jun 1;13(6):563–4. doi: 10.1038/nbt0695-563.
  106. Langabeer S., Gale R., Harvey R., Cook R., Mackinnon S., Linch D. Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia. 2002 Mar 4;16(3):393–9. doi: 10.1038/sj.leu.2402392.
  107. Gaydos C.A., Manhart L.E., Taylor S.N., Lillis R.A., Hook E.W., Klausner J.D., et al. Molecular Testing for Mycoplasma genitalium in the United States: Results from the AMES Prospective Multicenter Clinical Study. Munson E, editor. J Clin Microbiol. 2019 Sep 4;57(11). doi: 10.1128/JCM.01125-19.
  108. Gushchin A.E., Ryzhikh P.G., Khayrullina G.A., Kisina V.I. An Algorithm of a Laboratory Examination of Patients for Neisseria Gonorrhoeae, Chlamydia Trachomatis, Mycoplasma Genitalium and Trichomonas Vaginalis Infections Using the Polymerase Chain Reaction and the Transcriptional Amplification Reaction. Klin dermatologiya i Venerol. 2015;14(2):74. doi: 10.17116/klinderma201514274-81.
  109. ГУЩИН А.Е., БУРЦЕВ О.А., РЫЖИХ П.Г., ГОМБЕРГ М.А., ШИПУЛИН Г.А. Мониторинг лечения пациентов с инфекцией, вызванной Mycoplasma genitalium с помощью методов ПЦР и НАСБА в реальном времени. КЛИНИЧЕСКАЯ ДЕРМАТОЛОГИЯ И ВЕНЕРОЛОГИЯ. 2009;4:58–63.
  110. Wiesenfeld H.C., Manhart L.E. Mycoplasma genitalium in Women: Current Knowledge and Research Priorities for This Recently Emerged Pathogen. J Infect Dis. 2017 Jul 15;216(suppl_2):S389–95. doi: 10.1093/infdis/jix198.
  111. Iverson-Cabral S.L., Wood G.E., Totten P.A. Analysis of the Mycoplasma genitalium MgpB Adhesin to Predict Membrane Topology, Investigate Antibody Accessibility, Characterize Amino Acid Diversity, and Identify Functional and Immunogenic Epitopes. Balish MF, editor. PLoS One. 2015 Sep 18;10(9):e0138244. doi: 10.1371/journal.pone.0138244.
  112. Latimer R.L., Vodstrcil L., De Petra V., Fairley C.K., Read T.R., Williamson D., et al. Extragenital Mycoplasma genitalium infections among men who have sex with men. Sex Transm Infect. 2020 Feb;96(1):10–8. doi: 10.1136/sextrans-2019-054058.
  113. Ong J.J., Aung E., Read T.R.H., Fairley C.K., Garland S.M., Murray G., et al. Clinical Characteristics of Anorectal Mycoplasma genitalium Infection and Microbial Cure in Men Who Have Sex With Men. Sex Transm Dis. 2018 Aug;45(8):522–6. doi: 10.1097/OLQ.0000000000000793.
  114. Gatski M., Martin D.H., Theall K., Amedee A., Clark R.A., Dumestre J., et al. Mycoplasma genitalium infection among HIV-positive women: prevalence, risk factors and association with vaginal shedding. Int J STD AIDS. 2011 Mar;22(3):155–9. doi: 10.1258/ijsa.2010.010320.
  115. Madsen A.M.R., Thorsteinsson K., Lebech A.-M., Storgaard M., Katzenstein T.L., Rönsholt F.F., et al. Prevalence and significance of Mycoplasma genitalium in women living with HIV in Denmark. BMC Res Notes. 2017 Dec 7;10(1):468. doi: 10.1186/s13104-017-2776-5.
  116. Правительство России. Перечень социально значимых заболеваний (утв. постановлением Правительства РФ от 1 декабря 2004 г. N 715). Российская Федерация; 2020.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Shedko E.D., Goloveshkina E.N., Akimkin V.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».